Keep An Eye On IFRX, VNDA, DXCM…

(RTTNews) - What's moving these stocks?

1. InflaRx N.V. (IFRX)

InflaRx is a clinical-stage biopharmaceutical company.

The stock closed Wednesday's trading at $2.59, and was up 32.43% after-hours.

News: The company reported positive results from the phase IIb study of lead drug candidate IFX-1.

IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody is under phase IIb study dubbed SHINE in patients with moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease. Yesterday, InflaRx announced positive results from the open-label extension (OLE) part of the study.

2.Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals is a revenue genrating biopharmaceutical company

The stock closed Wednesday's trading at $13.14, and was up 19.86% after-hours.

News: The company announced better-than-expected financial results for the third quarter ended September 30, 2019 and provided full-year revenue guidance.

Net income in the third quarter was $100.42 million or $1.84 per share compared with $7.17 million or $0.13 per share in the corresponding quarter last year. Third-quarter earnings were favored by an income tax benefit of $88.1 million. Analysts earnings expectation was $0.07 per share.

Revenue in the third quarter rose to $59.49 million from $49.14 million in the same quarter a year ago.

Looking forward to full year, the company expects revenue to be in the range of $215 million to $225 million. Analysts currently expect the company to report revenue of $224.8 million.

3.DexCom, Inc. (DXCM)

DexCom is a medical device company, focusing on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

The stock closed Wednesday's trading at $153.12, and was up 19.51% after-hours.

News: The company reported Street-beating earnings in the third quarter ended September 30, 2019, and raised FY2019 revenue outlook.

Net income was $45.8 million, or $0.50 per share, for the third quarter compared with $46.6 million, or $0.52 per share, for the same quarter last year.

Net income on an adjusted basis rose to $60.4 million, or $0.65 per share from $15.9 million, or $0.18 per share in the year-earlier period. Analysts had a consensus earnings estimate of $0.20 per share.

Revenue in the third quarter grew 49% to $396.3 million, from $266.7 million in the year-earlier quarter.

The company has raised its revenue expectation to the range of $1.425 billion to $1.450 billion compared to previous expectations of $1.325 billion to $1.375 billion. Analysts forecast revenue of $1.37 billion.

4.Livongo Health, Inc. (LVGO)

Livongo Health is a medical device company that provides digital health management solutions to patients with chronic conditions.

The stock closed Wednesday's trading at $21.20, and was up 14.76% after-hours.

News: The company reported upbeat financial results for the third quarter ended September 30, 2019, and provided robust fourth-quarter and full-year revenue outlook.

Net loss for the third quarter was $19.73 million or $0.27 per share compared with net loss of $10.56 million or $0.64 per share in the same quarter a year ago.

On a non-GAAP basis, net loss narrowed to $3.38 million or $0.05 per share from $9.08 million or $0.55 per share in the prior-year quarter. Analysts had expected a loss of $0.13 per share.

Total revenue for the quarter was $46.66 million, up 148% year-over-year from $18.78 million.

Looking forward to fourth quarter, the company expects revenue in the range of $49.0 million and $49.5 million. The consensus estimate is $45.85 million.

For 2019, the company sees revenue in the range of $168.5 million and $169.0 million, compared with the consensus estimate of $161.89 million.

5.Career Education Corporation (CECO)

Career Education Corporation is an educational services company.

The stock closed Wednesday's trading at $14.90, and was up 13.15% after-hours.

News: The company reported strong financial results for the third quarter ended September 30, 2019, announced share buyback, and provided fourth-quarter and full-year outlook.

Third-quarter net income rose to $18.2 million or $0.25 per share from $14.9 million or $0.21 per share for the prior-year quarter.

Adjusted earnings per share were $0.33 in the third quarter versus $0.25 in the year-ago quarter. Analysts had estimated $0.24 per share.

Revenue in the third quarter increased 6.4 percent to $155.0 million as compared to $145.7 million in the year-earlier period.

Looking forward to fourth quarter, the company expects adjusted earnings per share to be in the range of $0.27 to $0.29. This is compared with the street estimate of $0.24 per share.

For the full year, the company sees adjusted earnings to be in the range of $1.32 to $1.34 per share and revenue growth is expected between 6.0 percent and 6.5 percent. The consensus estimate for earnings is at $1.24 and for revenue growth is at 5 percent.

On November 4, 2019, the Board of Directors of the company approved a new stock repurchase program of up to $50 million of outstanding common stock.